Key statistics
On Friday, Ovid Therapeutics Inc (1OT:MUN) closed at 1.02, 52.24% above the 52 week low of 0.67 set on Jun 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.02 |
---|---|
High | 1.02 |
Low | 1.02 |
Bid | 1.03 |
Offer | 1.08 |
Previous close | 0.985 |
Average volume | 1.20k |
---|---|
Shares outstanding | 70.97m |
Free float | 59.68m |
P/E (TTM) | -- |
Market cap | 81.62m USD |
EPS (TTM) | -0.4218 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
- Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
- Ovid Therapeutics to Present at Upcoming September Investor Conferences
- Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
- Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
- Ovid Therapeutics to Present at Upcoming August Investor Conferences
- Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
- eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
- Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
- Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
- Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
More ▼